Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.78 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | NEK2 | P51955 | 2/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.64 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.64 |
| ▸ | PIM1 | P11309 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406226 | 0.94 | PLK1 (0.84) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL4398132 | 0.88 | PLK1 (0.84) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL2989078 | 0.88 | PLK1 (0.74) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL4397905 | 0.87 | PLK1 (0.81) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL4405105 | 0.87 | PLK1 (0.83) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL3145169 | 0.87 | PLK1 (0.81) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL4405077 | 0.87 | PLK1 (0.81) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL4398410 | 0.87 | PLK1 (0.82) | PLK1PLK3CYP3A4CYP2C9NEK2 | |
| SCHEMBL4403598 | 0.86 | PLK1 (0.80) | PLK1PLK3CYP3A4CYP2C9 | |
| SCHEMBL4402857 | 0.86 | PLK1 (0.83) | PLK1PLK3CYP3A4CYP2C9NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056525-A1 | 5- AND 6- SUBSTITUTED BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056525-A1 | 5- AND 6- SUBSTITUTED BENZIMIDAZOLE THIOPHENE COMPOUNDS | CYP3A5, CYP2B6, CYP3A4 | PLK1 836/4885PLK3 1941/4885CYP3A4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.